Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs).

被引：0
|
作者：
Dasari, Arvind
Li, Daneng
Sung, Max W.
Tucci, Christopher
Kauh, John S.
Kania, Marek K.
Paulson, Andrew Scott
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] City Hope Comprehens Canc Ctr, Dept Med Oncol, Duarte, CA USA
[3] Beckman Res Inst, Duarte, CA USA
[4] Tisch Canc Inst Mt Sinai, New York, NY USA
[5] Hutchison MediPharma, Florham Pk, NJ USA
[6] Eli Lilly & Co, Bridgewater, NJ USA
[7] Hutchison MediPharma Int Inc, Florham Pk, NJ USA
[8] Texas Oncol US Oncol Network, Dallas, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4610
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
    Dasari, Arvind
    Shen, Chan
    Halperin, Daniel
    Zhao, Bo
    Zhou, Shouhao
    Xu, Ying
    Shih, Tina
    Yao, James C.
    JAMA ONCOLOGY, 2017, 3 (10) : 1335 - 1342
  • [32] Radioligand Therapy in Patients with Lung Neuroendocrine Tumors: A Systematic Review on Efficacy and Safety
    Malandrino, Pasqualino
    Feola, Tiziana
    Mikovic, Nevena
    Cannavale, Giuseppe
    Di Molfetta, Sergio
    Altieri, Barbara
    Mancini, Camilla
    Ferolla, Piero
    Colao, Annamaria
    Faggiano, Antongiulio
    SEMINARS IN NUCLEAR MEDICINE, 2024, 54 (04) : 570 - 580
  • [33] Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States
    Lee, Mi Ri
    Harris, Cynthia
    Baeg, Kiwoon Joshua
    Aronson, Anne
    Wisnivesky, Juan P.
    Kim, Michelle Kang
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (11) : 2212 - +
  • [34] Efficacy and Safety of Everolimus in Metastatic Gastroenteropancreatic Neuroendocrine Tumors
    Ambrosio, M. R.
    Guerra, A.
    Lupo, S.
    Bondanelli, M.
    Sartori, S.
    Pansini, G.
    Degli Uberti, E.
    Zatelli, M. C.
    NEUROENDOCRINOLOGY, 2012, 96 : 17 - 18
  • [35] Streptozotocin in pancreatic neuroendocrine tumors: a focus on efficacy and safety
    La Salvia, Anna
    Bellino, Stefania
    Fanciulli, Giuseppe
    EXPERT OPINION ON PHARMACOTHERAPY, 2025, 26 (02) : 115 - 118
  • [36] Safety and Tolerability of Lanreotide Autogel/Depot (LAN) in Patients (pts) with Neuroendocrine Tumours (NETs): Pooled Analysis of Clinical Studies
    Phan, A. T.
    Wolin, E. M.
    Fisher, G. A.
    Ruszniewski, P.
    Pavel, M.
    Liyanage, N.
    Mirakhur, B.
    Braun, S.
    Caplin, M.
    Vinik, A., I
    NEUROENDOCRINOLOGY, 2017, 105 : 206 - 206
  • [37] Efficacy and safety of surufatinib in the treatment of advanced solid tumors: a systematic evaluation and meta-analysis
    Cai, Tianying
    Cheng, Yonglang
    Du, Yichao
    Tan, Peng
    Li, Tongxi
    Chen, Yifan
    Gao, Lin
    Fu, Wenguang
    ONCOLOGY LETTERS, 2023, 25 (06)
  • [38] Characteristics of patients with neuroendocrine tumors in the United States: A study of 392,412 patients.
    Reddy, Ravali A.
    Liao, Cheng-I
    Johnson, Caitlin Ruth
    Tian, Chunqiao
    Darcy, Kathleen M.
    Kapp, Daniel Stuart
    Chan, John K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] Racial differences in the incidence and survival of patients with neuroendocrine tumors (NETs).
    Sarshekeh, Amir Mehrvarz
    Gu, Dian
    Zhou, Shouhao
    Bo, Zhao
    Shen, Chan
    Dasari, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [40] Surufatinib combined with transarterial embolization versus surufatinib monotherapy in patients with liver metastatic neuroendocrine tumors: Study protocol for a prospective, randomized, controlled trial
    Li, Ruizhen
    Li, Xiaofen
    You, Xin
    Su, Minggang
    Liu, Yuzhi
    Ke, Nengwen
    Cao, Dan
    CANCER MEDICINE, 2024, 13 (08):
12345